Abstract: Objective To explore the cytotoxic responses of spleen T lymphocytes (CTL) in BALB/c mice induced by recombinant HSP110-HER2/neu ICD complex.Methods Tumor-bearing mouse model was immunized by HSP110-HER2/neu ICD complex.The IFN-γ level secreted by activated spleen T lymphocytes was detected by enzyme linked immunospot assay (ELISPOT).The corresponding CTL activity was measured by granzyme release assay.Results The BALB/c mouse model of human mammary tumor highly expressing HER2/neu was established. HSP110-HER2/neu ICD complex immunization led to a significantly higher level of INF-γ than that in HSP110-P789-797 immunized and HER2/neu ICD immunized mice.HSP110-HER2/neu ICD complex immunized animals also show significant CTL activity.The results of immunohistochemical staining showed that the number of blue spots in the PBS group was 4.57 ± 1.33,HSP110 group 6.83 ± 2.08,HER2/neu ICD group 16.17 ± 2.86,HSP110-P789-797 group 43.67 ± 4.78,and SP110-HER2/neu ICD group 76.51 ± 8.17.The number of IFN-γ-secreting spleen lymphocytes in the HSP110-HER2/neu ICD group was significantly higher than that in the HSP110-P789-797 group,and that of HSP110-P789-797 group was significantly higher than that of HER2/neu ICD group ( P < 0.01 ).The target cell-killing rate of the PBS group was ( 8.15 ± 1.27) %,HSP110 group (9.51 ± 1.51 ) %,HER2/neu ICD group ( 14.03 ± 2.45 ) %,HSP110-P789-797 group ( 25.99 ± 3.04 ) % and HSP110-HER2/neu ICD group (38.15 ± 3.95) % ( all P < 0.01 ).Conclusions HSP110-HER2/neu ICD complex can promote the proliferation and maturation of T lymphocytes into CTLs,and might be used as anti-tumor vaccine to induce potent cytotoxic T lymophocyte immunoresponse against specific tumor cells.